The National Healthcare Security Administration (NHSA) has announced that the one-site negotiation and price bidding for the adjustment of the National Reimbursement Drug List (NRDL) will be conducted from October 27 to 30 in Beijing, with results anticipated to be released next month. The updated version of the NRDL is scheduled to be implemented starting January 1, 2025.
Since the NHSA’s establishment in 2018, there have been a total of six rounds of NRDL negotiations. These negotiations have resulted in the addition of 446 drugs, leading to a cumulative expenditure of the medical insurance fund exceeding RMB 340 billion (USD 47.8 billion) during the agreement period. This has benefited approximately 800 million people and has driven total drug sales to reach RMB 500 billion (USD 70.24 billion).
The 7th round of NRDL adjustment, initiated by the NHSA on July 1, 2024, confirmed the participation of 162 generic name drugs in the negotiation and price bidding process. Between October 16-18, 2024, representatives from the NHSA and a pharmacoeconomic expert panel held separate communications with each pharmaceutical company involved, discussing expectations for price reductions.- Flcube.com
